Onyx Pharma, Market Perform - M&A Rumors Fuel Investors Interest and Stock Movement
Recent news about “possible acquisition of Onyx pharma” is not a surprise in light of the upcoming verdict on Carfilzomib’s (PhIIb, next-generation proteasome inhibitor, Relapsed and Refractory Multiple Myeloma – R/R MM) and recent settlement over Regorafenib (BAY73-4506, PhIII) with Bayer. Onyx product pipeline focuses only in oncology. We have prepared a matrix of key players in oncology by indications and also rank order the suitors based on their needs and synergy, “Who could be the most suitable partner?” For more details, please read our report released on 30th November, 2011 on Onyx pharma titled “M&A Rumors Fuel Investors Interest and Stock Movement”
COMPANIES MENTIONED
ONYX PHARMA
ONYX PHARMA
